Table of Contents Author Guidelines Submit a Manuscript
Genetics Research International
Volume 2016 (2016), Article ID 8348450, 7 pages
Research Article

Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells

1College of Biotechnology, Misr University for Science and Technology, Giza, Egypt
2Center of Research and Development, Misr University for Science and Technology, Giza, Egypt

Received 27 June 2016; Revised 25 September 2016; Accepted 29 September 2016

Academic Editor: Norman A. Doggett

Copyright © 2016 Hussein Sabit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Colon cancer is the third most commonly diagnosed cancer in the world, and it is the major cause of morbidity and mortality throughout the world. The present study aimed at treating colon cancer cell line (HCT116) with different chemotherapeutic drug/drug combinations (procaine, vorinostat “SAHA,” sodium phenylbutyrate, erlotinib, and carboplatin). Two different final concentrations were applied: 3 μM and 5 μM. Trypan blue test was performed to assess the viability of the cell before and after being treated with the drugs. The data obtained showed that there was a significant decrease in the viability of cells after applying the chemotherapeutic drugs/drug combinations. Also, DNA fragmentation assay was carried out to study the effect of these drugs on the activation of apoptosis-mediated DNA degradation process. The results indicated that all the drugs/drug combinations had a severe effect on inducing DNA fragmentation. Global DNA methylation quantification was performed to identify the role of these drugs individually or in combination in hypo- or hypermethylating the CpG dinucleotide all over the genome of the HCT116 colon cancer cell line. Data obtained indicated that different combinations had different effects in reducing or increasing the level of methylation, which might indicate the effectiveness of combining drugs in treating colon cancer cells.